H.C. Wainwright raised the firm’s price target on Verrica Pharmaceuticals to $13 from $12 and keeps a Buy rating on the shares. The analyst sees Ycanth “tailwinds across the board” post the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRCA:
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
- VRCA Earnings this Week: How Will it Perform?
- Verrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options Traders
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition